Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16682335 | 0.95 | TDP1 (0.41) | ADRB3TDP1TSHRALDH1A1CA12 | |
| SCHEMBL1284218 | 0.91 | MEN1 (0.41) | ADRB3TDP1TSHRCA12CA1 | |
| SCHEMBL6249070 | 0.90 | CA12 (0.38) | ADRB3TDP1TSHRLMNAALDH1A1 | |
| SCHEMBL18067956 | 0.88 | CA12 (0.39) | ADRB3TDP1TSHRALDH1A1CA12 | |
| SCHEMBL16682325 | 0.87 | KCNH2 (0.49) | ADRB3LMNANPC1RAB9A | |
| SCHEMBL18067955 | 0.86 | ADRB3 (0.41) | ADRB3LMNAALDH1A1CA12CA1 | |
| SCHEMBL6181840 | 0.84 | CA12 (0.40) | ADRB3TDP1TSHRLMNAALDH1A1 | |
| SCHEMBL1027194 | 0.83 | KDM4E (0.36) | ADRB3LMNAKDM4EPOLBCYP1A2 | |
| SCHEMBL991922 | 0.82 | PDK2 (0.53) | TDP1TSHRALDH1A1CA12CA1 | |
| SCHEMBL992923 | 0.82 | BCHE (0.35) | PDK2KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2008-02-07 | — | — | US | disclosed |
| US-7282498-B2 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-20050059826-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION | 2005-03-17 | — | — | US | disclosed |
| US-20040220253-A1 | Synthesis of pyrrole amides | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
| US-6743817-B2 | AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR BRAIN RECEPTORS; ANXIOLYTICS, ANTIDEPRESSANTS, TREATING SLEEP AND PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2004-06-01 | — | — | US | disclosed |
| US-6656941-B2 | Aryl substituted tetrahydroindazoles | NEUROGEN CORPORATION | 2003-12-02 | — | — | US | disclosed |
| EP-1339681-A1 | SYNTHESIS OF FUSED PYRROLECARBOXAMIDES | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| EP-1326831-A1 | SUBSTITUTED FUSED PYRROLEIMINES AND PYRAZOLEIMINES | NEUROGEN CORPORATION (US) | 2003-07-16 | — | — | EP | disclosed |
| EP-1315703-A1 | ARYL SUBSTITUTED TETRAHYDROINDAZOLES AND THEIR USE AS LIGANDS FOR THE GABA-A RECEPTOR | NEUROGEN CORPORATION (US) | 2003-06-04 | — | — | EP | disclosed |
| US-20020151718-A1 | Synthesis of pyrrole amides | PFIZER INC. | 2002-10-17 | — | — | US | disclosed |
| US-20020128236-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NEUROGEN CORPORATION | 2002-09-12 | — | — | US | disclosed |
| WO-2002046155-A1 | SYNTHESIS OF FUSED PYRROLECARBOXAMIDES | PFIZER PRODUCTS INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| US-20020055524-A1 | Novel aryl substituted tetrahydroindazoles as ligands of the GABA receptor | NEUROGEN CORPORATION | 2002-05-09 | — | — | US | disclosed |
| WO-2002020492-A1 | ARYL SUBSTITUTED TETRAHYDROINDAZOLES AND THEIR USE AS LIGANDS FOR THE GABA-A RECEPTOR | NEUROGEN CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002020480-A1 | SUBSTITUTED FUSED PYRROLEIMINES AND PYRAZOLEIMINES | NEUROGEN CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220253-A1 | Synthesis of pyrrole amides | GABRA5, GABRA2, GABRA1 | ADRB3 251/4885TDP1 4115/4885TSHR 255/4885 |
| US-20050059826-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | NPSR1, GABRE, CHRNE | ADRB3 146/4885TDP1 968/4885TSHR 319/4885 |
| US-20020128236-A1 | Substituted fused pyrroleoximes and fused pyrazoleoximes | HTR1A, GABRA1, GABRE | ADRB3 166/4885TDP1 492/4885TSHR 555/4885 |
| US-20020151718-A1 | Synthesis of pyrrole amides | GABRA5, GABRA2, GABRA1 | ADRB3 251/4885TDP1 4115/4885TSHR 255/4885 |
| US-20020055524-A1 | Novel aryl substituted tetrahydroindazoles as ligands of the GABA receptor | GABRA1, GABRB1, GABRA3 | ADRB3 50/4885TDP1 698/4885TSHR 276/4885 |
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NPSR1, GABRE, CHRNE | ADRB3 146/4885TDP1 968/4885TSHR 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.